SCHEMBL310393

SCHEMBL310393

CCOc1cc(N2CCC(N3CCN(S(C)(=O)=O)CC3)CC2)c(CC)cc1Nc1nccc(-c2c(-c3ccc(OCC)c(C(=O)Nc4c(F)cccc4F)c3)nc3ccccn23)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 15/20 1.00
INSR P06213 11/20 1.00
LCK P06239 3/20 0.91
MAPK14 Q16539 3/20 0.91
AURKB Q96GD4 3/20 0.91
AURKA O14965 2/20 0.91
IKBKB O14920 1/20 0.91
CHUK O15111 1/20 0.91
RPS6KA4 O75676 1/20 0.91
PAK3 O75914 1/20 0.91
ABL1 P00519 1/20 0.91
NTRK1 P04629 1/20 0.91
FYN P06241 1/20 0.91
FES P07332 1/20 0.91
HCK P08631 1/20 0.91
FGFR1 P11362 1/20 0.91
INSRR P14616 1/20 0.91
FER P16591 1/20 0.91
FLT4 P35916 1/20 0.91
KDR P35968 1/20 0.91

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310484 0.98 IGF1R (1.00) IGF1RINSRLCKMAPK14AURKB
SCHEMBL311108 0.97 IGF1R (0.97) IGF1RINSRLCKMAPK14AURKB
SCHEMBL29391496 0.95 IGF1R (1.00) IGF1RINSRLCKMAPK14AURKB
SCHEMBL309890 0.95 IGF1R (1.00) IGF1RINSRLCKMAPK14AURKB
SCHEMBL310884 0.92 EGFR (0.88) IGF1RINSRLCKMAPK14AURKB
SCHEMBL13226237 0.91 IGF1R (0.92) IGF1RINSRLCKMAPK14AURKB
SCHEMBL310380 0.90 IGF1R (1.00) IGF1RINSRLCKMAPK14AURKB
SCHEMBL310706 0.90 IGF1R (1.00) IGF1RINSRLCKMAPK14AURKB
SCHEMBL310328 0.90 IGF1R (0.85) IGF1RINSRLCKMAPK14AURKB
SCHEMBL310555 0.89 EGFR (0.85) IGF1RINSRLCKMAPK14AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 IGF1R 633/4885INSR 814/4885LCK 49/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 IGF1R 633/4885INSR 814/4885LCK 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.